Kymera Therapeutics, Inc. Stock Price, News & Analysis

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced the pricing of a $250.8 million public offering of common stock and pre-funded warrants. The company is offering 5,044,500 shares at $44.00 per share and 655,500 pre-funded warrants at $43.9999 each.

The offering includes a 30-day option for underwriters to purchase up to 855,000 additional shares. The proceeds will support Kymera's pipeline of preclinical and clinical degrader programs. The offering is expected to close on June 30, 2025, with Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen, and Leerink Partners acting as joint book-running managers.

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $250.0 million of common stock and pre-funded warrants. The company is also granting underwriters a 30-day option to purchase up to an additional $37.5 million of shares.

The proceeds will be used to advance Kymera's pipeline of preclinical and clinical degrader programs targeting immunological diseases. Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen and Leerink Partners are serving as joint book-running managers for the offering.

Kymera Therapeutics (NASDAQ: KYMR) announced that Sanofi will advance KT-485, their next-generation oral IRAK4 degrader, into clinical testing while discontinuing development of KT-474. KT-485 demonstrated enhanced selectivity, potency, and favorable safety in preclinical testing.

Under their collaboration agreement, Kymera received a $20 million milestone payment in Q2 2025 and remains eligible for up to $975 million in potential milestones, plus double-digit royalties. Kymera maintains the option for a 50/50 development and profit share of KT-485 in the U.S.

Gilead Sciences (NASDAQ: GILD) and Kymera Therapeutics (NASDAQ: KYMR) have entered into an exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders for cancer treatment. The collaboration focuses on developing a new type of drug designed to remove CDK2, a key protein in tumor growth, rather than just inhibiting it.

Under the agreement, Kymera could receive up to $750 million in total payments, including $85 million in upfront and potential option exercise payments, plus tiered royalties ranging from high single-digit to mid-teens on net sales. Kymera will lead research activities, while Gilead will gain global rights upon exercising its option. The deal is expected to impact Gilead's 2025 EPS by approximately $0.02-$0.03.

Kymera Therapeutics announced positive Phase 1 results for KT-621, their first-in-class oral STAT6 degrader medicine. The trial demonstrated >90% STAT6 degradation in blood at doses above 1.5mg and complete degradation in both blood and skin at MAD doses ≥50mg. The drug showed impressive efficacy with TARC reduction up to 37% and Eotaxin-3 reduction up to 63%, comparable or superior to dupilumab. KT-621 exhibited excellent safety with no serious adverse events and a profile undifferentiated from placebo. The Phase 1 study included 118 healthy volunteers across single and multiple ascending dose cohorts. The company plans to advance KT-621 through their ongoing BroADen Phase 1b trial in atopic dermatitis patients, with data expected in Q4 2025, followed by Phase 2b trials in AD and asthma starting in Q4 2025 and Q1 2026 respectively.

Kymera Therapeutics (NASDAQ: KYMR) has scheduled a video webcast for June 2, 2025, at 8:00 a.m. ET to present results from their Phase 1 clinical trial of KT-621. The trial evaluated single and multiple-ascending doses of KT-621 in healthy volunteers. The company, which focuses on developing oral small molecule degrader medicines for immunological diseases, will make the presentation available through their website, with a replay and copy of the presentation accessible afterward. Interested parties can register for the webcast through a provided link or access it through the Investors section of Kymera's website.

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in three major investor conferences in June 2025:

- Jefferies Global Healthcare Conference in New York on June 5 at 8:10 a.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 10 at 3:20 p.m. ET
- Wolfe Research Virtual Biotech Day on June 26 (one-on-one meetings only)

Live webcasts of the presentations will be available on Kymera's website under the Investors section, with replays archived for later viewing.

Kymera Therapeutics (NASDAQ: KYMR) presented new preclinical data for KT-621, their first-in-class oral STAT6 degrader, at the American Thoracic Society International Conference. The data showed that KT-621 demonstrated comparable or superior activity to dupilumab in a chronic asthma model, both preventing and reversing disease progression. The company has completed Phase 1 healthy volunteer SAD/MAD trials with data expected in June 2025. Their BroADen Phase 1b trial in atopic dermatitis is ongoing with results expected in Q4 2025. Kymera plans to initiate two parallel Phase 2b trials in atopic dermatitis and asthma in Q4 2025 and Q1 2026, respectively. The preclinical results suggest KT-621 could offer dupilumab-like efficacy with the convenience of a daily oral medication.

Kymera Therapeutics (NASDAQ: KYMR) has unveiled KT-579, a first-in-class oral IRF5 degrader program targeting multiple immuno-inflammatory diseases. The drug candidate demonstrates potent and selective targeting of IRF5, a master regulator of immunity that has been historically difficult to drug. KT-579 has shown promising results in preclinical studies, with efficacy comparable or superior to existing treatments in lupus and RA models. Key highlights include:

• Achieved >90% degradation across multiple species with low oral doses
• Demonstrated superior efficacy to current standards in lupus and RA models
• Showed favorable safety profile up to 200-fold projected human efficacious levels
• Effectively blocked multiple inflammatory pathways in patient samples

The company plans to begin Phase 1 clinical testing in early 2026, targeting diseases including rheumatoid arthritis, lupus, Sjögren's, and IBD.